Status:
COMPLETED
COVID-19 Blood Pressure Endothelium Interaction Study (OBELIX)
Lead Sponsor:
NHS Greater Glasgow and Clyde
Collaborating Sponsors:
University of Glasgow
Conditions:
COVID
Hypertension
Eligibility:
All Genders
30-60 years
Brief Summary
The current COVID-19 pandemic (caused by the SARS-CoV-2 virus) represents the biggest medical challenge in decades. Whilst COVID-19 mainly affects the lungs it also affects multiple organ systems, inc...
Detailed Description
COVID-19 is pandemic and, though it primarily affects the lungs, there is evidence of cardiovascular system involvement. Mechanistically, SARS-CoV-2, following proteolytic cleavage of its S protein by...
Eligibility Criteria
Inclusion
- Admission between 01/04/2020 and 31/12/2020 Clinically suspected or PCR confirmed COVID-19 Age 30-60 years No history of hypertension or current drug treatment for hypertension
Exclusion
- Inability to give informed consent/lack of capacity Non-English speakers BMI \>40 eGFR \<60 ml/min Pregnancy History of Cancer within 5 years Persistent atrial fibrillation Severe illness, at investigator discretion Prescription of BP lowering drugs Corticosteroid (chronic use) Immunosupressive agents NSAIDs (chronic use)
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2021
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT04409847
Start Date
June 1 2020
End Date
July 1 2021
Last Update
November 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NHS Greater Glasgow and Clyde
Glasgow, United Kingdom